Skip to main content

Volume 11 Supplement 1

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review


Edited by Josef Smolen

Publication of this supplement has been sponsored by F. Hoffmann-La Roche.

  1. Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, whi...

    Authors: Andrea Rubbert-Roth and Axel Finckh
    Citation: Arthritis Research & Therapy 2009 11(Suppl 1):S1

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2022 Speed
    9 days submission to first editorial decision for all manuscripts (Median)
    149 days submission to accept (Median)

    2022 Usage 
    17,226 Altmetric mentions